Literature DB >> 26622883

Evaluation of MMP-2, MMP-9, TIMP-1, TIMP-2, NGAL and MMP-9/NGAL complex in urine and sera from patients with bladder cancer.

Serena Ricci1, Dario Bruzzese2, Angelina DI Carlo3.   

Abstract

The identification of biomarkers in urine or serum samples from patients with bladder cancer is urgently required for the development of non-invasive methods for the diagnosis of bladder carcinoma and to facilitate follow-up surveillance, to combat the high progression and recurrence rates of this type of cancer. The current study measured the content of matrix metalloproteinase (MMP)-2 and -9, as well as tissue inhibitor of metalloproteinase (TIMP)-1 and -2 in the urine and sera of 41 patients with bladder cancer by ELISA. The association between levels of MMP-2 and -9 and TIMP-1 and -2, and tumor grade and stage were investigated to verify whether these molecules are involved in tumor differentiation. Statistical analysis of the data revealed that urinary TIMP-1 levels were significantly higher in the high grade group compared with those of the low grade samples (P=0.022). The results also revealed a significantly differing distribution of TIMP-1 expression between Ta and T1 stage specimens (P=0.040). The corresponding area under the curves (AUCs) were 0.72, with a sensitivity of 0.70 and specificity of 0.75. In addition, neutrophil gelatinase-associated lipocalin (NGAL) and MMP-9/NGAL complex levels in the sera were measured. All molecules evaluated were detected in the sera of the patients studied. In particular, tumors staged as non-muscle invasive (Ta and T1), demonstrated significantly higher NGAL levels compared with those of muscle invasive (>T1) bladder cancer (32.8 ng/ml vs. 16.2 ng/ml; P=0.029). The discriminatory ability of NGAL expression was confirmed by receiver operating characteristic curve analysis that revealed an AUC of 0.75, a sensitivity of 0.88 and a specificity of 0.67. These data indicated that urinary TIMP-1 and serum NGAL may be useful non-invasive biomarkers to provide clinical information for bladder cancer disease management. Multicenter, prospective studies are required to confirm these preliminary results.

Entities:  

Keywords:  bladder carcinoma; matrix metalloproteinase-2; matrix metalloproteinase-9; neutrophil gelatinase-associated lipocalin; sera; tissue inhibitor of metalloproteinase-1; tissue inhibitor of metalloproteinase-2; urine

Year:  2015        PMID: 26622883      PMCID: PMC4580016          DOI: 10.3892/ol.2015.3558

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

Review 1.  Matrix metalloproteinases: a tail of a frog that became a prince.

Authors:  Constance E Brinckerhoff; Lynn M Matrisian
Journal:  Nat Rev Mol Cell Biol       Date:  2002-03       Impact factor: 94.444

2.  Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy.

Authors:  Shahrokh F Shariat; Niccolo Passoni; Aditya Bagrodia; Varun Rachakonda; Evanguelos Xylinas; Brian Robinson; Payal Kapur; Arthur I Sagalowsky; Yair Lotan
Journal:  BJU Int       Date:  2014-01       Impact factor: 5.588

Review 3.  Epidemiology and risk factors of urothelial bladder cancer.

Authors:  Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan
Journal:  Eur Urol       Date:  2012-07-25       Impact factor: 20.096

4.  Association between smoking and risk of bladder cancer among men and women.

Authors:  Neal D Freedman; Debra T Silverman; Albert R Hollenbeck; Arthur Schatzkin; Christian C Abnet
Journal:  JAMA       Date:  2011-08-17       Impact factor: 56.272

Review 5.  The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer.

Authors:  Subhankar Chakraborty; Sukhwinder Kaur; Sushovan Guha; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2012-03-31

6.  NGAL controls the metastatic potential of anaplastic thyroid carcinoma cells.

Authors:  Vincenzo Volpe; Zelinda Raia; Luca Sanguigno; Domenico Somma; Paola Mastrovito; Fortunato Moscato; Stefano Mellone; Antonio Leonardi; Francesco Pacifico
Journal:  J Clin Endocrinol Metab       Date:  2012-11-12       Impact factor: 5.958

7.  Role of cytokeratins, nuclear matrix proteins, Lewis antigen and epidermal growth factor receptor in human bladder tumors.

Authors:  Angelina Di Carlo; Daniela Terracciano; Angela Mariano; Andrea Oliva; Massimo D'Armiento; Vincenzo Macchia
Journal:  Int J Oncol       Date:  2003-09       Impact factor: 5.650

8.  Bladder cancer. Clinical practice guidelines in oncology.

Authors:  James E Montie; Robert R Bahnson; Samuel M Cohen; Beverly Drucker; Mario A Eisenberger; Rizk El-Galley; Harry W Herr; Gary R Hudes; Timothy M Kuzel; Paul H Lange; Anthony Patterson; Alan Pollack; Jerome P Richie; John Seigne; William U Shipley; Eric J Small; Donald L Trump; Philip J Walther; Timothy G Wilson
Journal:  J Natl Compr Canc Netw       Date:  2005-01       Impact factor: 11.908

9.  Gelatinolytic activities (matrix metalloproteinase-2 and -9) and soluble extracellular domain of Her-2/neu in pleural effusions.

Authors:  Angelina Di Carlo; Angela Mariano; Daniela Terracciano; Claudia Mazzarella; Sonia Galzerano; Marcellino Cicalese; Ciriaco Cecere; Vincenzo Macchia
Journal:  Oncol Rep       Date:  2007-08       Impact factor: 3.906

10.  Neutrophil Gelatinase-Associated Lipocalin (NGAL), Pro-Matrix Metalloproteinase-9 (pro-MMP-9) and Their Complex Pro-MMP-9/NGAL in Leukaemias.

Authors:  Sandrine Bouchet; Brigitte Bauvois
Journal:  Cancers (Basel)       Date:  2014-04-04       Impact factor: 6.639

View more
  12 in total

1.  Neutrophil gelatinase-associated lipocalin as a screening test in prostate cancer.

Authors:  Necati Muşlu; Bahadır Ercan; Serin Akbayır; Şenay Balcı; H Didem Ovla; Murat Bozlu
Journal:  Turk J Urol       Date:  2017-01-06

2.  Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry.

Authors:  Abduladim Hmmier; Michael Emmet O'Brien; Vincent Lynch; Martin Clynes; Ross Morgan; Paul Dowling
Journal:  BBA Clin       Date:  2017-03-06

3.  Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer.

Authors:  Luca Falzone; Saverio Candido; Rossella Salemi; Maria S Basile; Aurora Scalisi; James A McCubrey; Francesco Torino; Salvatore S Signorelli; Maurizio Montella; Massimo Libra
Journal:  Oncotarget       Date:  2016-11-08

4.  Nodal regulates bladder cancer cell migration and invasion via the ALK/Smad signaling pathway.

Authors:  Youkong Li; Wen Zhong; Min Zhu; Shengguo Hu; Xiaokang Su
Journal:  Onco Targets Ther       Date:  2018-10-05       Impact factor: 4.147

Review 5.  Revisiting Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Cancer: Saint or Sinner?

Authors:  Brigitte Bauvois; Santos A Susin
Journal:  Cancers (Basel)       Date:  2018-09-18       Impact factor: 6.639

Review 6.  Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).

Authors:  Marzena Wyganowska-Świątkowska; Mateusz Tarnowski; Daniel Murtagh; Ewa Skrzypczak-Jankun; Jerzy Jankun
Journal:  Int J Mol Med       Date:  2018-11-07       Impact factor: 4.101

7.  Dynamic urinary proteomic analysis in a Walker 256 intracerebral tumor model.

Authors:  Linpei Zhang; Yuqiu Li; Wenshu Meng; Yanying Ni; Youhe Gao
Journal:  Cancer Med       Date:  2019-05-15       Impact factor: 4.452

8.  Down-regulation of SOX18 inhibits laryngeal carcinoma cell proliferation, migration, and invasion through JAK2/STAT3 signaling.

Authors:  Yice Xu; Qingyuan Zhang; Jie Zhou; Zhaolong Li; Junyu Guo; Weina Wang; Wei Wang
Journal:  Biosci Rep       Date:  2019-07-05       Impact factor: 3.840

9.  ROC analysis of selected matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in psoriatic patients.

Authors:  Edyta K Glazewska; Marek Niczyporuk; Slawomir Lawicki; Maciej Szmitkowski; Monika Zajkowska; Magdalena Donejko; Andrzej Przylipiak
Journal:  Postepy Dermatol Alergol       Date:  2018-04-24       Impact factor: 1.837

10.  Low molecular weight proteins and enzymes in the urine of patients with bladder cancer - a pilot study.

Authors:  Zofia Marchewka; Beata Szymańska; Janusz Dembowski; Anna Długosz; Agnieszka Piwowar
Journal:  Cent European J Urol       Date:  2018-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.